Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma

Author:

Mohan Meera1ORCID,Chakraborty Rajshekhar2,Bal Susan3,Nellore Anoma4,Baljevic Muhamed5ORCID,D'Souza Anita1ORCID,Pappas Peter G.4,Berdeja Jesus G.6,Callander Natalie7,Costa Luciano J.3ORCID

Affiliation:

1. Division of Hematology/Oncology Medical College of Wisconsin Milwaukee Wisconsin USA

2. Multiple Myeloma and Amyloidosis Program Herbert Irving Comprehensive Cancer Center, Columbia University New York City New York USA

3. Division of Hematology and Medical Oncology University of Alabama at Birmingham Birmingham Alabama USA

4. Division of Infectious Diseases University of Alabama at Birmingham Birmingham Alabama USA

5. Division of Hematology/Oncology Vanderbilt‐Ingram Cancer Center Nashville Tennessee USA

6. Sarah Cannon Research Institute Nashville Tennessee USA

7. Department of Medicine, Division of Hematology and Oncologye University of Wisconsin Madison Wisconsin USA

Abstract

SummaryChimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T‐cell exhaustion, cytokine‐release syndrome and immune‐effector cell‐associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T‐cell and bispecific antibody therapies in MM patients.

Publisher

Wiley

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3